SLC5A2 and type 2 diabetes mellitus: The causes of DKA induced by SGLT2 inhibitors in T2DM may be related to higher glucagon levels, decreased inhibition of lipolysis and ketogenesis caused by reduced daily insulin requirements, and decreased urinary ketoexcretion (14, 15).